Morgan Stanley
ATHE

Morgan Stanley’s Alterity Therapeutics ATHE Stock Holding History

Morgan Stanley’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$339K Buy
63,065
+4,683
+8% +$20.4K ﹤0.01% 5726
2026
Q1 		$203K Sell
58,382
-5,300
-8% -$18K ﹤0.01% 5861
2025
Q4 		$196K Sell
63,682
-5,000
-7% -$19.1K ﹤0.01% 5943
2025
Q3 		$258K Buy
68,682
+10,381
+18% +$50.1K ﹤0.01% 5788
2025
Q2 		$238K Buy
58,301
+14,600
+33% +$57.3K ﹤0.01% 5786
2025
Q1 		$151K Sell
43,701
-700
-2% -$2.68K ﹤0.01% 5845
2024
Q4 		$147K Sell
44,401
-100
-0.2% -$159 ﹤0.01% 5897
2024
Q3 		$58.4K Sell
44,501
-3,894
-8% -$5.73K ﹤0.01% 6169
2024
Q2 		$87.6K Sell
48,395
-3,590
-7% -$7.22K ﹤0.01% 6006
2024
Q1 		$108K Sell
51,985
-58,169
-53% -$112K ﹤0.01% 5962
2023
Q4 		$274K Buy
110,154
+58,669
+114% +$145K ﹤0.01% 5825
2023
Q3 		$128K Sell
51,485
-700
-1% -$1.94K ﹤0.01% 5769
2023
Q2 		$146K Sell
52,185
-1,300
-2% -$3.69K ﹤0.01% 5780
2023
Q1 		$148K Buy
53,485
+1,049
+2% +$3.57K ﹤0.01% 5841
2022
Q4 		$183K Sell
52,436
-2,260
-4% -$8.64K ﹤0.01% 5703
2022
Q3 		$241K Sell
54,696
-4,830
-8% -$28.3K ﹤0.01% 5639
2022
Q2 		$364K Buy
59,526
+1,530
+3% +$10.8K ﹤0.01% 5582
2022
Q1 		$481K Buy
57,996
+2,010
+4% +$16.7K ﹤0.01% 5424
2021
Q4 		$403K Sell
55,986
-910
-2% -$9.87K ﹤0.01% 5675
2021
Q3 		$723K Sell
56,896
-5,930
-9% -$82.5K ﹤0.01% 5274
2021
Q2 		$817K Buy
62,826
+35
+0.1% +$474 ﹤0.01% 5202
2021
Q1 		$904K Buy
62,791
+4,581
+8% +$77.2K ﹤0.01% 4793
2020
Q4 		$780K Buy
58,210
+13,612
+31% +$214K ﹤0.01% 4799
2020
Q3 		$901K Buy
44,598
+2,048
+5% +$41.7K ﹤0.01% 4280
2020
Q2 		$506K Buy
42,550
+14,240
+50% +$90.5K ﹤0.01% 4588
2020
Q1 		$170K Buy
28,310
+2,010
+8% +$13.8K ﹤0.01% 4935
2019
Q4 		$205K Buy
26,300
+2,318
+10% +$23.3K ﹤0.01% 5403
2019
Q3 		$273K Buy
23,982
+1,162
+5% +$12.9K ﹤0.01% 4978
2019
Q2 		$299K Buy
22,820
+939
+4% +$15K ﹤0.01% 4846
2019
Q1 		$411K Buy
21,881
+40
+0.2% +$681 ﹤0.01% 4673
2018
Q4 		$280K Buy
21,841
+911
+4% +$15.8K ﹤0.01% 5137
2018
Q3 		$421K Buy
20,930
+1,191
+6% +$24.8K ﹤0.01% 5093
2018
Q2 		$373K Buy
19,739
+743
+4% +$14.8K ﹤0.01% 5273
2018
Q1 		$404K Buy
18,996
+1,297
+7% +$34.7K ﹤0.01% 5125
2017
Q4 		$552K Buy
17,699
+3,090
+21% +$96.9K ﹤0.01% 4917
2017
Q3 		$409K Buy
14,609
+830
+6% +$22.6K ﹤0.01% 4997
2017
Q2 		$315K Buy
13,779
+760
+6% +$18.9K ﹤0.01% 5079
2017
Q1 		$407K Buy
13,019
+860
+7% +$20.3K ﹤0.01% 4959
2016
Q4 		$198K Buy
12,159
+590
+5% +$15.8K ﹤0.01% 5357
2016
Q3 		$523K Buy
11,569
+3,490
+43% +$174K ﹤0.01% 4498
2016
Q2 		$383K Buy
8,079
+3,065
+61% +$118K ﹤0.01% 4585
2016
Q1 		$143K Buy
5,014
+2,703
+117% +$90.2K ﹤0.01% 5157
2015
Q4 		$100K Buy
2,311
+1,986
+611% +$101K ﹤0.01% 5401
2015
Q3 		$17K Sell
325
-75
-19% -$4.75K ﹤0.01% 6091
2015
Q2 		$28K Sell
400
-11
-3% -$826 ﹤0.01% 6039
2015
Q1 		$27K Sell
411
-64
-13% -$5.11K ﹤0.01% 5979
2014
Q4 		$46K Sell
475
-901
-65% -$97.4K ﹤0.01% 5840
2014
Q3 		$177K Buy
1,376
+238
+21% +$31.8K ﹤0.01% 5204
2014
Q2 		$155K Buy
1,138
+218
+24% +$24.9K ﹤0.01% 5280
2014
Q1 		$154K Buy
920
+519
+129% +$287K ﹤0.01% 5241
2013
Q4 		$168K Sell
401
-2,263
-85% -$677K ﹤0.01% 5108
2013
Q3 		$657K Buy
+2,664
New +$612K ﹤0.01% 4133

Other funds holding ATHE

GT
Greenleaf Trust Kalamazoo, Michigan $10.4B AUM 0.97% 1-Year Est. Return
HWM
HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
PCA
Providence Capital Advisors Charlotte, North Carolina $660M AUM 17.81% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return

Morgan Stanley's ATHE Position: Q2 2026 in Review

Morgan Stanley increased its Alterity Therapeutics (ATHE) stake by 8% in Q2 2026, buying an estimated $20.4K and bringing the position to 63,065 shares worth $339K. The position accounts for ﹤0.01% of the portfolio, ranked #5726.

Morgan Stanley first reported a position in ATHE in Q3 2013 and has held it in 52 quarters since. The position peaked at $904K in Q1 2021. 21 funds tracked by Wall St. Rank hold ATHE as of Q2 2026.

  • Morgan Stanley held 63,065 shares of Alterity Therapeutics worth $339K as of Q2 2026.
  • Morgan Stanley bought 4,683 Alterity Therapeutics shares in Q2 2026, an estimated $20.4K.
  • Alterity Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5726 holding.
  • Morgan Stanley first reported a position in Alterity Therapeutics in Q3 2013 and has held it in 52 quarters since.
  • Morgan Stanley's Alterity Therapeutics position peaked at $904K in Q1 2021.
  • 21 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.